Number of Shares] THESEUS PHARMACEUTICALS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • September 30th, 2021 • Theseus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THESEUS PHARMACEUTICALS, INC. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • November 3rd, 2022 • Theseus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Theseus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
Form of Indemnification AgreementForm of Indemnification Agreement • September 30th, 2021 • Theseus Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is made as of [•], 2021 by and between Theseus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [•] (“Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering the subject matter of this Agreement.
CONSULTING AGREEMENTConsulting Agreement • December 4th, 2023 • Theseus Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
THIS CONSULTING AGREEMENT (the “Agreement”), dated as of December 7, 2023 (the “Effective Date”), is between Theseus Pharmaceuticals, Inc., a Delaware corporation with a place of business at 314 Main Street, Suite 04-200, Cambridge, MA 02142, USA (“Company”) and David Kerstein, an individual having an address at 1 James Millen Rd., North Reading, MA 01864-2985 (“Consultant”). Consultant and Company (each a “Party”; collectively, the “Parties”) agree as follows:
AGREEMENT AND PLAN OF MERGER DATED AS OF DECEMBER 22, 2023 AMONG CONCENTRA BIOSCIENCES, LLC, CONCENTRA MERGER SUB II, INC. AND THESEUS PHARMACEUTICALS, INC.Agreement and Plan of Merger • December 22nd, 2023 • Theseus Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [●](this “Agreement”), is entered into by and between Concentra Biosciences, LLC, a Delaware limited liability company (the “Parent”), Concentra Merger Sub II, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the “Purchaser”), [●], a [●], as Rights Agent (as defined herein), and [●], solely in its capacity as the initial representative, agent and attorney in-fact of the Holders (the “Representative”).
December 7, 2023 Via Electronic Mail Tim ClacksonSeparation and Release Agreement • December 4th, 2023 • Theseus Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
As discussed, your employment with Theseus Pharmaceuticals, Inc. (the “Company”) will terminate on December 7, 2023. A copy of your Separation and Release Agreement is enclosed with this letter.
VIA ELECTRONIC MAIL William Shakespeare wcshake@gmail.com Re: Separation and Release Agreement Dear Bill: The purpose of this Separation and Release Agreement (the “Agreement”) is to confirm the terms regarding your separation of employment from...Separation and Release Agreement • November 13th, 2023 • Theseus Pharmaceuticals, Inc. • Pharmaceutical preparations
LEASE AGREEMENT 314 MAIN STREET CAMBRIDGE, MASSACHUSETTS LEASE SUMMARY SHEETLease Agreement • September 30th, 2021 • Theseus Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
THIS INDENTURE OF LEASE (this “Lease”) is hereby made and entered into on the Execution Date by and between Landlord and Tenant.
